Projects / Programmes source: ARIS

Metabolic disorders and lipodystrophy in slovenian HIV-infected patients, treated with highly active antiretroviral therapy

Research activity

Code Science Field Subfield
3.07.00  Medical sciences  Metabolic and hormonal disorders   

Code Science Field
B510  Biomedical sciences  Infections 
HIV infection, treatment, metabolic complication
Evaluation (rules)
source: COBISS
Researchers (5)
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  18372  PhD Andrej Janež  Metabolic and hormonal disorders  Researcher  2002 - 2004  668 
2.  19773  Primož Karner  Microbiology and immunology  Researcher  2002 - 2004  78 
3.  11348  PhD Mojca Matičič  Microbiology and immunology  Researcher  2002 - 2004  367 
4.  11347  PhD Janez Tomažič  Microbiology and immunology  Head  2002 - 2004  412 
5.  12180  PhD Ludvik Vidmar  Microbiology and immunology  Researcher  2002 - 2004  142 
Organisations (1)
no. Code Research organisation City Registration number No. of publicationsNo. of publications
1.  0312  University Medical Centre Ljubljana  Ljubljana  5057272000  77,465 
The etilogy of HIV-related metabolic syndrome has yet to be elucidated, but its manifestations are more clear: hypercholesterolemia, hypertrigleceridemia, insulin resistance, diabetes, fat atrophy (loss of subcutaneous fat in face and extremities), fat accomulation (central visceral adiposity, breast enlargement dorsocervical fat pad). The researchers have yet to arrive at even a common defenition for the problem generally referred to as lipodystrophy syndrome. The syndrome must likely has a multifactorial etiology. Early anecdotal reports led to the widespread assumptions that protease inhibitors (PIs) were directly responsible for these complications. However, it is unclear whethwr these effects are attributable to PI therapy per se, or are simply manifestations of improving overall health in the context of HIV disease. Critical issues that remin to be addressed include to need for uniform diagnostic criteria, identification of the sites of dysregulation and underlying mechanisms, determination of the prevalence and risk factors, evaluation of the clinical sequelae and development of optimal management strategies. The aim of the present study is: - to determine the prevalence of lipodystrophy and metabolic complications in a HIV-treated patient population in Slovenia. - to analyse the efficacy of switching from PI-containing to non-nucleoside reverse transcriptase inhibitor (NNRTI)- containing regimen in patients being on sustained virological success, in terms of lipid profile, insuline resistance, glucose tolerance and morphological abnormalities. - to follow the metabolic effects of different antiretroviral treatment regimens (different classes of antiretrovirals) longitudinally, to assess possible risk factors and a mechanism responsible for this syndrom.
Views history